Status:

COMPLETED

Patients Preference for Oral or i.v. Therapy

Lead Sponsor:

Odense University Hospital

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Until recently, bolus 5-flourouracil (FU) + folinic acid (FA) has been considered the standard chemotherapy for patients with colorectal cancer. Several studies have shown that Capecitabine is as effe...

Eligibility Criteria

Inclusion

  • Indication for treatment with a FU-regime
  • WHO Performance Status 0-1
  • Life expectancy \> 3 months
  • Adequate haematological, renal and hepatic functions
  • Adequate contraceptives
  • Written informed consent

Exclusion

  • Known CNS-metastases
  • Prior treatment with chemotherapy
  • Pregnant or breast feeding women
  • Current infection, unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis
  • other serious illness or medical conditions

Key Trial Info

Start Date :

December 1 2002

Trial Type :

INTERVENTIONAL

End Date :

April 1 2004

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00212589

Start Date

December 1 2002

End Date

April 1 2004

Last Update

September 21 2005

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Department of Oncology, Esbjerg Hospital

Esbjerg, Denmark, 6700

2

Department of Oncology, Odense University Hospital

Odense, Denmark, 5000

3

Department of Oncology, Sonderborg Hospital

Sønderborg, Denmark, 6400

4

Department of Oncology, Vejle Hospital

Vejle, Denmark, 7100